background
recent
ebola
viru
ebov
epidem
highlight
need
efficaci
virucid
product
help
prevent
infect
limit
spread
ebola
viru
diseas
howev
limit
data
efficaci
virucid
product
ebov
viru
high
biosafeti
level
avail
laboratori
worldwid
virucid
efficaci
antisept
disinfect
determin
use
european
standard
modifi
vaccinia
viru
ankara
mva
introduc
refer
viru
claim
virucid
activ
envelop
virus
hygien
hand
rub
hand
wash
ebov
also
envelop
viru
suitabl
mva
surrog
need
proven
aim
studi
test
vitro
efficaci
four
povidon
iodin
pvpi
formul
ebov
pvpi
skin
cleanser
pvpi
surgic
scrub
pvpi
solut
pvpi
alcohol
solut
formul
test
mva
defin
test
condit
secondari
object
suitabl
mva
surrog
envelop
virus
like
ebov
assess
method
accord
standard
suspens
test
use
mva
largevolum
plate
use
ebov
increas
test
sensit
exclud
potenti
aftereffect
product
test
clean
gl
bsa
dirti
gl
bsa
mll
erythrocyt
condit
mva
concentrationcontact
time
valu
obtain
mva
verifi
ebov
result
viral
titr
mva
ebov
reduc
clean
dirti
condit
applic
test
product
second
conclus
product
show
excel
virucid
efficaci
ebov
demonstr
import
role
pvpi
play
help
prevent
limit
spread
ebola
viru
diseas
efficaci
test
virus
help
inform
implement
guidanc
peopl
potenti
expos
ebov
confirm
excel
virucid
efficaci
pvpi
envelop
virus
mva
found
suitabl
surrog
envelop
virus
like
ebov
decemb
ebola
viru
ebov
epidem
began
guinea
march
ebola
viru
outbreak
offici
commun
world
health
organ
outbreak
west
africa
mostli
affect
guinea
sierra
leon
liberia
largest
complex
outbreak
sinc
viru
discov
ebov
spread
mainli
contact
bodi
fluid
symptomat
patient
contamin
surfac
healthcar
worker
famili
friend
close
contact
ebola
patient
highest
risk
becom
infect
andor
spread
viru
ebov
diseas
fatal
rate
specif
antivir
treatment
vaccin
current
avail
although
phase
clinic
trial
advanc
ebola
vaccin
candid
start
autumn
current
treatment
includ
gener
care
support
vital
organ
function
includ
fluid
replac
therapi
kidney
dialysi
blood
transfus
plasma
replac
therapi
absenc
ebovspecif
treatment
efficaci
disinfect
antisept
product
use
help
prevent
spread
infect
addit
hygien
measur
wear
glove
contact
blood
bodi
fluid
medic
mask
goggl
face
shield
identifi
import
protect
ebov
transmiss
consid
ebov
deadli
threat
clear
chemic
disinfect
proven
virucid
efficaci
use
achiev
ensur
disinfect
pass
virucid
activ
test
perform
complianc
good
laboratori
practic
countryspecif
standard
europ
describ
standard
determin
virucid
activ
involv
three
nonenvelop
virus
polioviru
type
adenoviru
type
strain
adenoid
murin
noroviru
recent
envelop
viru
interestingli
sever
year
german
guidelin
virucid
test
includ
test
disinfect
envelop
virus
includ
mva
bovin
viral
diarrhoea
viru
bvdv
allow
product
effect
envelop
virus
label
limit
spectrum
virucid
activ
although
envelop
virus
deem
suscept
disinfect
may
react
differ
nonenvelop
virus
regard
concentr
requir
applic
time
activ
ingredi
therefor
necessari
test
envelop
model
viru
claim
virucid
activ
envelop
virus
despit
usual
role
envelop
virus
bloodborn
pathogen
eg
human
immunodefici
hepat
b
hepat
c
virus
also
respons
sever
outbreak
includ
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
coronaviru
mersco
influenza
pandem
hemorrhag
fever
virus
ebov
centc
committe
establish
standardis
european
test
method
requir
antimicrobi
efficaci
chemic
disinfect
antisept
intend
implement
new
test
viru
assess
antimicrobi
efficaci
envelop
test
virus
choic
model
virus
great
import
establish
standard
test
method
requir
model
virus
includ
high
resist
disinfect
dri
combin
simpl
viru
propag
cell
cultur
eg
grow
high
titr
expert
suggest
envelop
viru
modifi
vaccinia
viru
ankara
mva
refer
viru
claim
virucid
activ
envelop
virus
hygien
hand
rub
hand
wash
viru
shown
produc
similar
result
vaccinia
viru
strain
elstre
virucid
test
chosen
low
biosafeti
level
mean
pose
hazard
employe
perform
test
known
environment
stabil
practic
laboratori
use
contrast
ebov
lethal
viru
requir
highest
biosafeti
level
investig
therefor
avail
test
laboratori
worldwid
povidon
iodin
pvpi
known
long
time
broad
spectrum
microbicid
bacteria
fungi
protozoan
virus
watersolubl
complex
element
iodin
bound
carrier
polyvinylpyrrolidon
aqueou
medium
chemic
equilibrium
develop
releas
activ
antimicrobi
agent
iodin
complexlink
iodin
build
reservoir
deliveri
therebi
microbicid
activ
maintain
cytotox
effect
high
concentr
iodin
reduc
oxid
potenc
pvpi
enabl
iodin
releas
react
rapidli
function
group
amino
acid
nucleotid
well
doubl
bond
fatti
acid
result
manifold
destruct
variou
structur
enzym
microb
virus
develop
resist
mechan
broad
oxid
attack
appear
almost
imposs
compel
vitro
data
gener
virucid
activ
pvpi
avail
demonstr
efficaci
envelop
virus
mump
herp
simplex
rubella
measl
influenza
human
immunodefici
corona
virus
nonenvelop
virus
includ
adeno
rota
polio
coxsackieand
rhinoviru
studi
investig
vitro
efficaci
four
pvpi
hand
wash
hand
rub
product
ebov
addit
explor
whether
mva
would
suitabl
test
viru
assess
virucid
activ
ebov
also
envelop
viru
compar
vitro
virucid
efficaci
pvpi
formul
mva
efficaci
ebov
four
pvpi
antisept
product
test
studi
includ
pvpi
skin
cleanser
pvpi
surgic
scrub
pvpi
solut
brand
name
betadin
manufactur
mundipharma
limburg
germani
pvpialcohol
solut
contain
alcohol
ethanol
brand
name
betasept
also
manufactur
mundipharma
test
viru
suspens
prepar
infect
suscept
cell
mva
institut
anim
hygien
veterinari
public
health
univers
leipzig
cell
cell
line
establish
fibroblast
newborn
hamster
kidney
use
viru
cultiv
suspens
test
viru
inocul
cell
supernat
replac
minimum
essenti
medium
mem
biochrom
ag
germani
foetal
calf
serum
fc
sigmaaldrich
germani
host
cell
collect
cell
line
veterinari
medicin
cclv
friedrich
loeffler
institut
germani
cultiv
humid
atmospher
co
viru
cultiv
confluent
monolay
maximum
age
day
use
cell
incub
cell
exhibit
cytopath
effect
approxim
day
cell
frozen
thaw
twice
follow
centrifug
g
min
viru
titr
upscal
ultra
centrifug
g
h
pellet
resuspend
ml
medium
aliquot
viru
suspens
store
ebov
strain
zair
cdc
atlanta
use
test
viru
vero
cell
cell
line
establish
cercopithecu
aethiop
kidney
use
viru
cultiv
suspens
test
host
cell
cultiv
humid
atmospher
co
cell
fed
dulbecco
minimum
essenti
medium
dmem
supplement
heatinactiv
fc
nonessenti
amino
acid
viru
cultiv
confluent
monolay
maximum
age
day
use
cell
debri
separ
low
speed
centrifug
g
min
aliquot
viru
suspens
store
liquid
nitrogen
use
cell
cultur
evalu
disinfect
activ
virus
target
cell
often
sensit
activ
ingredi
howev
cytotox
effect
seen
vitro
affect
way
product
behav
vivo
cytotox
test
product
disinfect
test
commonli
overcom
dilut
virusdisinfect
mixtur
order
determin
cytotox
test
product
serial
dilut
tenfold
mem
dilut
one
part
volum
water
standardis
hard
instead
viru
suspens
mix
one
part
volum
organ
load
clean
condit
gl
bovin
serum
albumin
bsa
dirti
condit
gl
bsa
mll
erythrocyt
eight
part
volum
test
product
aliquot
test
product
dilut
inocul
six
well
microtitr
plate
contain
cell
suspens
cell
cell
cultur
observ
cytotox
effect
incub
time
later
use
suspens
test
test
carri
accord
one
part
volum
mva
viru
suspens
titr
least
tissu
cultur
infecti
dose
tcid
ml
one
part
volum
organ
load
mix
eight
part
volum
pvpi
hand
wash
hand
rub
product
test
product
examin
undilut
solut
specifi
contact
time
virucid
activ
immedi
suppress
dilut
nine
volum
icecold
medium
mem
fc
without
delay
assay
serial
dilut
due
immedi
titrat
aftereffect
product
could
occur
infect
determin
mean
end
point
dilut
titrat
microtitr
plate
aliquot
dilut
place
six
well
steril
polystyren
flatbottom
microtitr
plate
contain
cell
cultur
observ
cytopath
effect
eight
day
inocul
viru
control
doubli
distil
water
appli
instead
test
product
test
perform
clean
condit
gl
bsa
dirti
condit
gl
bsa
mll
erythrocyt
interf
substanc
viru
titr
determin
use
method
express
tcid
ml
includ
standard
deviat
titr
reduct
present
differ
viru
titr
contact
test
product
control
viru
titr
differ
given
reduct
factor
includ
confid
interv
reduct
viru
titr
log
correspond
inactiv
regard
evid
suffici
virucid
activ
calcul
perform
accord
inactiv
assay
use
larg
volum
plate
lvp
method
verif
concentrationcontact
time
valu
ebov
usual
low
titr
ebov
harvest
cell
cultur
result
rang
log
tcid
ml
demonstr
least
log
reduct
viru
titr
necessari
test
mixtur
contain
low
viru
titr
undergo
detoxif
molecular
siev
use
sensit
assay
lvp
molecular
siev
microspin
hr
column
method
choic
ebov
process
reduc
titr
larg
filament
virus
log
lvp
high
volum
lowest
appar
noncytotox
dilut
inactiv
assay
test
mixtur
ad
detector
cell
line
cultur
monitor
virusspecif
effect
use
method
larger
reduct
viru
titr
shown
even
lower
viral
load
inactiv
test
conduct
one
part
ebov
suspens
mix
either
gl
bsa
clean
condit
gl
bsa
mll
erythrocyt
dirti
condit
interf
substanc
virusprotein
mixtur
ad
part
dilut
test
product
except
pvpi
skin
cleanser
dilut
contact
time
test
mixtur
pvpi
solut
pvpi
surgic
scrub
pvpialcohol
solut
ad
ml
icecold
medium
result
dilut
test
product
pvpi
skin
cleanser
test
mixtur
ad
ml
correspond
dilut
dilut
sampl
ad
aliquot
microtitr
plate
well
contain
indic
cell
cell
cultur
medium
cell
cultiv
incub
period
day
inspect
microscop
viru
foci
virusinduc
chang
cell
morpholog
fig
viral
titr
calcul
follow
number
infecti
viru
particl
determin
poisson
distribut
accord
cpmp
guidelin
use
follow
formula
c
concentr
virus
test
mixtur
p
denot
probabl
detect
viru
v
plate
volum
v
v
total
volum
probabl
averag
number
tcid
calcul
use
follow
formula
deriv
taylor
seri
c
concentr
virus
test
mixtur
dilut
factor
predilut
sampl
p
denot
probabl
detect
viru
v
w
plate
volum
per
well
n
number
inocul
well
n
p
number
success
infect
well
howev
one
tcid
equival
infecti
viru
particl
natur
logarithm
likelihood
p
ln
impli
least
trial
necessari
success
infect
well
therefor
factor
need
calcul
tcid
addit
poisson
formula
use
dilut
factor
predilut
sampl
consid
use
lvp
lowest
appar
noncytotox
dilut
test
mixtur
ad
icecold
medium
specifi
contact
time
immedi
suppress
virucid
effect
test
product
make
precis
method
short
incub
time
aftereffect
test
product
sampl
exclud
compar
endpoint
titrat
method
method
might
sometim
difficult
carri
necessari
pipet
quickli
enough
particularli
wear
protect
suit
work
ebov
addit
detect
residu
viru
improv
test
larg
sampl
volum
case
small
number
viru
particl
present
poisson
formula
determin
pvpi
kinet
low
high
protein
load
use
new
european
test
viru
virucid
efficaci
envelop
virus
mva
test
concentr
contact
period
chosen
order
observ
point
test
prepar
produc
effici
viru
inactiv
demonstr
virucid
efficaci
disinfect
antisept
product
requir
produc
log
reduct
viru
titr
least
log
reduct
factor
produc
test
product
clean
dirti
condit
time
point
shown
tabl
viral
titr
mva
reduc
clean
dirti
condit
applic
undilut
dilut
pvpi
solut
pvpi
surgic
scrub
pvpi
skin
cleanser
littl
pvpialcohol
solut
similar
effect
except
dirti
condit
dilut
reduct
factor
reduct
clean
dirti
condit
concentrationdepend
virucid
activ
seen
pvpi
product
tabl
dirti
condit
minimum
concentr
pvpi
need
log
reduct
mva
time
higher
contact
time
gl
versu
gl
time
higher
contact
time
gl
versu
gl
clean
condit
tabl
titr
ebov
present
control
sampl
compar
test
run
valu
around
log
tcid
ml
pvpi
prepar
test
reduc
ebov
viral
titr
log
reduct
factor
fig
correspond
reduct
ebov
viral
titr
product
test
recent
european
guidelin
lack
envelop
test
viru
use
evalu
hygien
hand
rub
hand
wash
due
recent
ebola
outbreak
mva
introduc
refer
viru
envelop
virus
howev
still
uncertainti
whether
surrog
would
suitabl
danger
virus
ebov
studi
investig
antivir
efficaci
pvpi
mva
verifi
concentr
contact
time
find
ebov
found
pvpi
effect
ebov
mva
similar
concentr
contact
time
paramet
fact
compar
result
pvpi
skin
cleanser
predilut
ebov
test
mva
even
resist
pvpi
dirti
condit
ebov
result
suggest
mva
suitabl
surrog
test
viru
safe
use
test
virucid
efficaci
antisept
product
ebov
anoth
studi
steinmann
et
al
hand
wash
contain
pvpi
activ
vaccinia
viru
bvdv
within
nonenvelop
virus
test
howev
fingerpad
test
simul
practic
condit
pvpi
contain
soap
superior
sanitis
nonenvelop
virus
although
minimum
contact
time
hygien
hand
rub
hand
wash
defin
investig
four
pvpi
product
minimum
contact
time
studi
kinet
pvpi
product
mva
time
assum
suffici
degre
effect
would
shown
howev
four
undilut
prepar
effici
inactiv
european
test
viru
mva
littl
protein
load
eg
blood
sputum
may
influenc
activ
disinfect
includ
pvpi
product
studi
rel
small
differ
virucid
activ
pvpi
compar
clean
dirti
condit
dilut
product
dirti
condit
higher
concentr
pvpi
need
inactiv
mva
clean
condit
result
suspens
test
allow
virucid
efficaci
product
predict
give
inform
effect
practic
order
improv
knowledg
timeconcentr
relationship
hand
rub
hand
wash
product
reflect
daili
need
clinic
surround
practic
test
would
necessari
describ
bactericid
test
simul
practic
condit
volunt
howev
envelop
harmless
viru
avail
use
inocul
volunt
year
ago
test
vaccinia
viru
fingertip
volunt
perform
howev
today
longer
justifi
ethic
hand
hygien
infect
control
procedur
clearli
demonstr
efficaci
remain
cornerston
effort
reduc
spread
infect
accord
guidelin
hand
hygien
import
infect
prevent
control
measur
ebov
gener
two
method
hand
hygien
social
hand
wash
hygien
hand
disinfect
social
clean
hand
achiev
use
soap
water
remov
transient
microorgan
social
hand
wash
practis
perform
routin
task
clinic
area
hygien
hand
disinfect
carri
alcoholbas
hand
rub
toto
remov
destroy
transient
microorgan
may
prolong
effect
recommend
exampl
sinc
skin
routin
sourc
infect
transmiss
use
pvpi
hand
disinfect
may
altern
recommend
alcoholbas
hand
rub
medic
soap
contain
pvpi
avail
thu
hygien
measur
hand
wash
support
virucid
effect
pvpi
could
extend
beyond
surgic
use
healthcar
profession
patient
famili
member
profession
risk
infect
could
use
product
protect
exposur
patient
pvpi
soap
shown
similar
efficaci
alcoholbas
hand
sanitis
noroviru
hand
wash
model
chlorhexidineand
triclosanbas
hand
wash
howev
effect
noroviru
suspens
test
practic
applic
test
anoth
studi
neonat
icu
set
pvpi
base
hand
wash
show
antimicrobi
efficaci
compar
alcoholbas
hand
rub
superior
use
soap
water
alon
relat
ebov
similar
virus
pvpi
recommend
hand
disinfect
laboratori
deal
sampl
collect
patient
suspect
viral
haemorrhag
fever
result
studi
support
find
suggest
hand
wash
pvpi
base
product
help
prevent
infect
ebov
addit
hand
wash
pvpi
prepar
may
applic
reduc
spread
ebov
limit
use
intact
skin
also
administ
mucosa
mouth
nose
eye
urinari
genit
tract
treatment
potenti
entri
point
ebov
virus
may
appropri
prepar
highli
concentr
alcoholbas
product
pvpi
product
test
show
excel
efficaci
fast
virucid
activ
mva
ebov
littl
european
test
viru
mva
even
resist
pvpi
dirti
condit
ebov
therefor
consid
virucid
test
mva
suitabl
altern
claim
virucid
activ
envelop
virus
hygien
hand
rub
hand
wash
result
suggest
pvpi
repres
effect
measur
help
prevent
infect
limit
spread
ebola
viru
diseas
help
inform
implement
appropri
guidanc
peopl
expos
ebov
confirm
excel
virucid
efficaci
pvpi
envelop
virus
meg
respons
studi
design
perform
statist
analysi
provid
analysi
interpret
data
carri
virucid
test
mva
carri
virucid
test
ebov
provid
analysi
interpret
data
kk
carri
virucid
test
ebov
jz
particip
origin
plan
design
studi
contribut
interpret
result
well
manuscript
kr
particip
origin
plan
design
studi
contribut
interpret
result
well
manuscript
author
read
approv
final
manuscript
